

Advances in Plasma Oncology toward Clinical Translation

Guest Editors:

Prof. Dr. Annemie Bogaerts

Department of Chemistry,
University of Antwerp, Campus
Drie Eiken – Room B2.09,
Universiteitsplein 1, Wilrijk, BE-
2610 Antwerp, Belgium

Dr. Katharina Stapelmann

Department of Nuclear
Engineering, North Carolina State
University, Raleigh, North
Carolina, USA

Dr. Abraham Lin

Department of Chemistry,
Antwerp University, Antwerpen,
Belgium

Deadline for manuscript
submissions:

closed (1 January 2021)

Message from the Guest Editors


Dear Colleagues,

In the past decade, cold atmospheric plasmas (CAPs) have been under investigation for their potential for cancer treatment, thus opening field of plasma oncology. CAPs are tunable sources for the production and delivery of reactive oxygen and nitrogen species (RONS), which positions them as a unique tool to study intracellular redox pathways and for development as a novel redox therapy.

The role of the tumor microenvironment is attracting greater attention among plasma-cancer researchers. Strategies for combination therapy, e.g., immunotherapy, are also of great importance and are currently under development. In this Special Issue, we will publish original research papers that provide fundamental understanding into the mechanisms of CAPs in cancer treatment, ranging from computer modeling to in vitro and in vivo experiments and clinical trials.

Dr. Annemie Bogaerts
Dr. Katharina Stapelmann
Dr. Abraham Lin
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)